154 related articles for article (PubMed ID: 18984268)
1. Expression of Bcl-2 in olfactory neuroblastoma and its association with chemotherapy and survival.
Kim JW; Kong IG; Lee CH; Kim DY; Rhee CS; Min YG; Kim CW; Chung JH
Otolaryngol Head Neck Surg; 2008 Nov; 139(5):708-12. PubMed ID: 18984268
[TBL] [Abstract][Full Text] [Related]
2. Therapy and prognosis of intracranial invasive olfactory neuroblastoma.
Jiang GY; Li FC; Chen WK; Liu AM; Cai WQ
Otolaryngol Head Neck Surg; 2011 Dec; 145(6):951-5. PubMed ID: 21825099
[TBL] [Abstract][Full Text] [Related]
3. Olfactory neuroblastoma: the 22-year experience at one comprehensive cancer center.
Diaz EM; Johnigan RH; Pero C; El-Naggar AK; Roberts DB; Barker JL; DeMonte F
Head Neck; 2005 Feb; 27(2):138-49. PubMed ID: 15654688
[TBL] [Abstract][Full Text] [Related]
4. Expression of bcl-2 is associated with microvessel density in olfactory neuroblastoma.
Diensthuber M; Potinius M; Rodt T; Stan AC; Welkoborsky HJ; Samii M; Schreyögg J; Lenarz T; Stöver T
J Neurooncol; 2008 Sep; 89(2):131-9. PubMed ID: 18431543
[TBL] [Abstract][Full Text] [Related]
5. Clincopathological analysis of olfactory neuroblastoma.
Fukushima S; Sugita Y; Niino D; Mihashi H; Ohshima K
Brain Tumor Pathol; 2012 Oct; 29(4):207-15. PubMed ID: 22331316
[TBL] [Abstract][Full Text] [Related]
6. Calretinin staining facilitates differentiation of olfactory neuroblastoma from other small round blue cell tumors in the sinonasal tract.
Wooff JC; Weinreb I; Perez-Ordonez B; Magee JF; Bullock MJ
Am J Surg Pathol; 2011 Dec; 35(12):1786-93. PubMed ID: 22020045
[TBL] [Abstract][Full Text] [Related]
7. Combined modality therapy of esthesioneuroblastoma.
McLean JN; Nunley SR; Klass C; Moore C; Müller S; Johnstone PA
Otolaryngol Head Neck Surg; 2007 Jun; 136(6):998-1002. PubMed ID: 17547995
[TBL] [Abstract][Full Text] [Related]
8. Olfactory neuroblastoma: the University of Erlangen-Nuremberg experience 1975-2000.
Constantinidis J; Steinhart H; Koch M; Buchfelder M; Schaenzer A; Weidenbecher M; Iro H
Otolaryngol Head Neck Surg; 2004 May; 130(5):567-74. PubMed ID: 15138422
[TBL] [Abstract][Full Text] [Related]
9. The clinicopathological spectrum of olfactory neuroblastoma and sinonasal neuroendocrine neoplasms: Refinements in diagnostic criteria and impact of multimodal treatments on survival.
Turri-Zanoni M; Maragliano R; Battaglia P; Giovannardi M; Antognoni P; Lombardi D; Morassi ML; Pasquini E; Tarchini P; Asioli S; Foschini MP; Sessa F; Nicolai P; Castelnuovo P; La Rosa S
Oral Oncol; 2017 Nov; 74():21-29. PubMed ID: 29103747
[TBL] [Abstract][Full Text] [Related]
10. p63 Expression in olfactory neuroblastoma and other small cell tumors of the sinonasal tract.
Bourne TD; Bellizzi AM; Stelow EB; Loy AH; Levine PA; Wick MR; Mills SE
Am J Clin Pathol; 2008 Aug; 130(2):213-8. PubMed ID: 18628089
[TBL] [Abstract][Full Text] [Related]
11. Treatment modalities and outcomes of olfactory neuroblastoma.
Song CM; Won TB; Lee CH; Kim DY; Rhee CS
Laryngoscope; 2012 Nov; 122(11):2389-95. PubMed ID: 23070733
[TBL] [Abstract][Full Text] [Related]
12. Results of salvage therapy after failure of initial treatment for advanced olfactory neuroblastoma.
Kim HJ; Cho HJ; Kim KS; Lee HS; Kim HJ; Jung E; Yoon JH
J Craniomaxillofac Surg; 2008 Jan; 36(1):47-52. PubMed ID: 18312791
[TBL] [Abstract][Full Text] [Related]
13. Cytopathologic features of olfactory neuroblastoma.
Mahooti S; Wakely PE
Cancer; 2006 Apr; 108(2):86-92. PubMed ID: 16456848
[TBL] [Abstract][Full Text] [Related]
14. Proton-beam therapy for olfactory neuroblastoma.
Nishimura H; Ogino T; Kawashima M; Nihei K; Arahira S; Onozawa M; Katsuta S; Nishio T
Int J Radiat Oncol Biol Phys; 2007 Jul; 68(3):758-62. PubMed ID: 17398027
[TBL] [Abstract][Full Text] [Related]
15. Bcl-2 but not FOXP1, is an adverse risk factor in immunochemotherapy-treated non-germinal center diffuse large B-cell lymphomas.
Nyman H; Jerkeman M; Karjalainen-Lindsberg ML; Banham AH; Enblad G; Leppä S
Eur J Haematol; 2009 May; 82(5):364-72. PubMed ID: 19141121
[TBL] [Abstract][Full Text] [Related]
16. Expression of SGLT1, Bcl-2 and p53 in primary pancreatic cancer related to survival.
Casneuf VF; Fonteyne P; Van Damme N; Demetter P; Pauwels P; de Hemptinne B; De Vos M; Van de Wiele C; Peeters M
Cancer Invest; 2008 Oct; 26(8):852-9. PubMed ID: 18853313
[TBL] [Abstract][Full Text] [Related]
17. Olfactory neuroblastoma: 15 years of experience.
Kondo N; Takahashi H; Nii Y; Nagao J
Anticancer Res; 2012 May; 32(5):1697-703. PubMed ID: 22593448
[TBL] [Abstract][Full Text] [Related]
18. Olfactory neuroblastoma: a single-center experience.
König M; Osnes T; Jebsen P; Evensen JF; Meling TR
Neurosurg Rev; 2018 Jan; 41(1):323-331. PubMed ID: 28540633
[TBL] [Abstract][Full Text] [Related]
19. The potential role of Bcl-2 expression, apoptosis and cell proliferation (Ki-67 expression) in cases of gastric carcinoma and correlation with classic prognostic factors and patient outcome.
Tsamandas AC; Kardamakis D; Tsiamalos P; Liava A; Tzelepi V; Vassiliou V; Petsas T; Vagenas K; Zolota V; Scopa CD
Anticancer Res; 2009 Feb; 29(2):703-9. PubMed ID: 19331225
[TBL] [Abstract][Full Text] [Related]
20. Olfactory neuroblastoma: a review and update.
Faragalla H; Weinreb I
Adv Anat Pathol; 2009 Sep; 16(5):322-31. PubMed ID: 19700942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
